Skip to content
DataLookout
Menu

SANTORINI-MXNCT07930975

Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Proportion of Participants Achieving Risk-Based LDL-C Treatment Goals
Timeframe: Baseline (at enrollment; LDL-C measurement obtained within the preceding 12 months)

Secondary (15)

Proportion of Participants Achieving Risk-Based LDL-C Goals at 12 Months
Lipid-Lowering Treatment Patterns at Baseline and Follow-up
Proportion of Participants With Lipid-Lowering Treatment Intensification
Proportion of Participants With Clinical Inertia in Lipid-Lowering Treatment
Changes in Lipid Parameters From Baseline to 12 Months
Show 10 moreShow less
Proportion of Participants With Barriers to Lipid-Lowering Treatment Optimization
Proportion of Participants With High Medication Adherence
Proportion of Participants With Documented Statin Intolerance
Change in Glycated Hemoglobin (HbA1c) From Baseline to 12 Months
Change in High-Sensitivity C-Reactive Protein From Baseline to 12 Months
Change in Serum Creatinine From Baseline to 12 Months
Change in Health-Related Quality of Life Assessed by EQ-5D-5L
Change in Patient Activation Measure (PAM-13) Score
Change in Estimated Glomerular Filtration Rate From Baseline to 12 Months
Change in Urinary Albumin-to-Creatinine Ratio From Baseline to 12 Months

Arms and interventions

High and Very High Cardiovascular Risk Patients

Adults aged 18 years or older classified as having high or very high cardiovascular risk according to the 2019 ESC/EAS guidelines, who are receiving or have a clinical indication for lipid-lowering therapy. Participants will be consecutively enrolled at participating healthcare centers in Mexico and assessed at baseline and after 12 ± 2 months. Lipid levels, cardiovascular risk factors, lipid-lowering treatments, treatment intensification, medication adherence, and barriers to optimal lipid management will be recorded. All treatments will be prescribed according to routine clinical practice, without protocol-assigned interventions.

Drugs: Lipid-Lowering Therapy in Routine Clinical Practice

Sites

1 site in 1 country

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico City, Mexico City, Mexico